A response to 'Measles, mumps, rubella vaccine: Through a glass, darkly' by Drs AJ Wakefield and SM Montgomery and published reviewers' comments

Adverse Drug Reactions and Toxicological Reviews

Volumn 20, Issue 1, 2001, Pages 37-45

  Arlett, P ^a   Bryan, P ^b   Evans, S ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MMR; VACCINE;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HUMAN; INFANTILE AUTISM; MEASLES; MEASLES VACCINATION; MUMPS; NOTE; PATENT; POSTVACCINAL ENCEPHALITIS; RUBELLA; SEROCONVERSION; SUBACUTE SCLEROSING PANENCEPHALITIS; TREATMENT PLANNING; UTILIZATION REVIEW;

AUTISTIC DISORDER; CHILD; DIGESTIVE SYSTEM; GREAT BRITAIN; HUMANS; MEASLES-MUMPS-RUBELLA VACCINE; NERVOUS SYSTEM DISEASES; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; SUBACUTE SCLEROSING PANENCEPHALITIS; UNITED STATES; VIRAL INTERFERENCE;

EID: 0035018822     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Bloch AB, Orenstein WA, Steiler HC, et al. Health impact of measles vaccination in the United States. Pediatrics 1985; 76: 524-32.
2. Dyken PR, Cunningham SC, Ward LC. Changing character of subacute sclerosing panencephalitis in the United States. Pediatr Neural 1989; 6: 339-41.
3. Miller C, Farrington C P, Herbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales, 1970 to 1989. Int J Epidemiol 1992; 21: 998-1006.
4. Office for National Statistics. Twentieth Century Mortality Data for ICD9 on CD-ROM, 1979-1998.
5. Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am J Gastroenterol 2000; 95: 3507-12.
6. Thompson NP, Montgomery SM, Wadsworth ME, Pounder RE, Wakefield AJ. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. Eur J Gastroenterol Hepatol 2000; 12: 25-30.
7. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. Lancet i 1986; 939-42.
8. Sackett DL, Haynes, RB, Guyatt, GH, Tugwell, P. Clinical Epidemiology 2nd Edn. Boston, Little, Brown & Co. 1991, p 286-7.
9. Kaye JA, Melero-Montes MdM, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460-63.
10. Weibel RE, Carlson AJ, Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps and rubella vaccines using the RA 27/3 rubella virus. Proc Soc Exp Biol Med 1980; 165: 323-6.
11. Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps and rubella virus vaccines, singly and in combination. Pediatrics 1981; 68: 18-22.
12. Weibel RE, Buynak EB, McLean AA et al. Persistence of antibody in human subjects for 7 to 10 years following administration of combined measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1980; 165: 260-3.
13. Curr Probl Pharmacovigil 1995; 21: 9-10.
14. American Academy of Pediatrics. Measles. In: Peter G, ed. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994: 308-23.
15. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic Thrombocytopenic Purpura and MMR vaccine. Arch Dis Child 2001; 84: 227-9.
16. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, Waight PA. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-9.